New Project to Develop Human Monoclonal Antibodies for Neutralizing SARS-Cov-2

New Project to Develop Human Monoclonal Antibodies for Neutralizing SARS-Cov-2

  • Research Stash
  • News
  • 1.8K

The Council of Scientific and Industrial Research (CSIR), through its New Millennium Indian Technology Leadership Initiative (NMITLI) program, has approved a project towards the development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in patients. This project on the generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team.

Monoclonal antibody therapy is a form of immunotherapy designed to produce immunity to a disease or to enhance resistance by the immune system. This new project aims to generate hmAbs to SARS-CoV-2 from the gradual recovery phase of COVID-19 patients and select high affinity and neutralizing antibodies. The project also aims to anticipate future adaptation of the virus and generate hmAbs clones that can neutralize the mutated virus so that could be readily used for combating future SARS-CoV infections.

This industry-academia collaboration comprises National Centre for Cell Science (NCCS) Pune; Indian Institute of Technology (IIT), Indore; PredOmix Technologies Ltd, Gurugram; and Bharat Biotech International Ltd (BBIL), Hyderabad. Vaccines and biotherapeutics maker BBIL is leading the project to develop human monoclonal antibodies (hmAbs) for COVID-19 infection. BBIL will be the commercial partner and responsible for subsequent development and commercialization of the hmAbs generated.

DG-CSIR, Dr. Shekhar C Mande commented that “As the research into SARS-CoV-2 is in early days and our understanding is evolving each day, it is critical that we deploy all possible strategies to combat the virus. Hence, CSIR is exploring all avenues and we are supporting new ideas which have clear deployment strategy”.

CSIR is leading the fight against COVID-19 using a multi-pronged approach and multiple models of engagement. CSIR labs themselves are developing technologies and products and are working with industry and public sector undertakings for deployment. NMITLI is a flagship program of CSIR aimed to support new ideas and projects from academic institutions and industries. (ISW)

Umashankar Mishra

If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook

DG-CSIR, Dr. Shekhar C Mande commented that “As the research into SARS-CoV-2 is in early days and our understanding is evolving each day, it is critical that we deploy all possible strategies to combat the virus. Hence, CSIR is exploring all avenues and we are supporting new ideas which have clear deployment strategy”.

CSIR is leading the fight against COVID-19 using a multi-pronged approach and multiple models of engagement. CSIR labs themselves are developing technologies and products and are working with industry and public sector undertakings for deployment. NMITLI is a flagship program of CSIR aimed to support new ideas and projects from academic institutions and industries. (ISW)

Umashankar Mishra

If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook

" }

Taiwan places top 10 in international math, physics olympiads

Taiwan competitors placed in the top 10 in the international math and physics Olympiads, bringing home a total of 11 medals, the Ministry of Education announced July 23.

  • News
  • 3K
Read more
Freshly harvested fruits

Wild Blood Fruit A Source of Natural Red Colourant May Be Domesticated

Blood fruit is a woody climber and it is very popular among tribes in the Northeastern states, Andaman and Nicobar Islands and Bangladesh. The fruit is not only tasty and rich in anti-oxidant but is also a good source of dye for the local handicraft industry.  Now researchers have developed a standard nursery protocol for its propagation.

  • News
  • 2.9K
Read more

Antibody targeting IL-17B/RB proved effective for pancreatic cancer

Of all battles against cancer, when it comes to the therapeutics for pancreatic cancer, more than ever, it is too little and too late. That is why, when Dr. Wen-Hwa Lee’s team developed an antibody and proved that it can extend the life of lab mice to twice longer than its compared group, the participating scientists are excited, for they have pushed the milestone one step further in finding the therapeutics for pancreatic cancer patients

  • News
  • 2.4K
Read more

Internet is huge! Help us find great content

Newsletter

Never miss a thing! Sign up for our newsletter to stay updated.

About

Research Stash is a curated collection of tools and News for S.T.E.M researchers

Have any questions or want to partner with us? Reach us at [email protected]

Navigation

Submit